Takeda Divests Europe OTCs In $670m Deal As Rumors Swirl Of Japan Biz Sale
Takeda will divest a portfolio containing OTC drugs and dietary supplements to Denmark's Orifarm, while rumors suggest the company is poised to offload its substantial Japanese consumer healthcare business.
You may also be interested in...
Consumer Health Business News: Rebrands for Takeda OTC And Reckitt, DSM Acquires, Enzymatica Raises Funds
A round-up of the latest consumer health industry news: Takeda completes the sale of its Japanese OTC business, which has rebranded as Alinamin; Reckitt drops the "Benckiser" from its name to signal new approach; Enzymatica looks to raise funds as COVID continues to bite; and Royal DSM expands its portfolio through a new deal with Amyris.
HBW Insight reveals the biggest consumer health deals of 2020, and identifies growing private equity investment, portfolio streamlining by major players and pharma firms exiting OTC as the major drivers of M&A activity.
Brazil's Hypera is paying Takeda $0.8bn for a portfolio of brands which will make it the "undisputed leader" in the South American country's OTC market.